Literature DB >> 32293921

NASAL GLUCAGON DELIVERY IS MORE SUCCESSFUL THAN INJECTABLE DELIVERY: A SIMULATED SEVERE HYPOGLYCEMIA RESCUE.

Julie A Settles, Gregg Francis Gerety, Erik Spaepen, Jeffrey Gideon Suico, Christopher J Child.   

Abstract

Objective: A severe hypoglycemia (SH) episode is an acute, high-stress moment for the caregivers of persons with diabetes (PWD). We compared the success rates of nasal glucagon (NG) and injectable glucagon (IG) administration for PWD-trained and untrained users in treating simulated SH episodes.
Methods: Thirty-two PWD-trained users and 33 untrained users administered NG and IG to high-fidelity manikins simulating treatment of an SH emergency. Simulation rooms resembled common locations with typical diabetic supplies and stressor elements mimicking real-life SH environments. Success rate and time to administer glucagon were measured.
Results: Of all the PWD-trained and untrained users, 58/64 (90.6%) could successfully deliver NG, while 5/63 (7.9%) could successfully deliver IG. For NG simulations, 28/31 (90.3%) PWD-trained users and 30/33 (90.9%) untrained users could successfully administer the dose (mean time 47.3 seconds and 44.5 seconds, respectively). For IG simulations, 5/32 (15.6%) PWD-trained users successfully injected IG (mean time 81.8 seconds), whereas none (0/31 [0%]) of the untrained users were successful. Reasons for unsuccessful administration of NG included oral administration and incomplete pushing of the device plunger. For IG, inability to perform reconstitution steps, partial dose delivery, and injection at an inappropriate site were the causes for failure.
Conclusion: With or without training, the success rate for administering NG was 90.6%, whereas it was only 7.9% for IG. NG was easily and quickly administered even by untrained users, whereas training was necessary for successful administration of IG. NG may expand the community of caregivers who can help PWD during an SH episode. Abbreviations: IG = injectable glucagon; NG = nasal glucagon; PWD = person with diabetes; SH = severe hypoglycemia; T1D = type 1 diabetes; T2D = type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32293921     DOI: 10.4158/EP-2019-0502

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  6 in total

1.  Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial.

Authors:  Thomas R Pieber; Ronnie Aronson; Ulrike Hövelmann; Julie Willard; Leona Plum-Mörschel; Kim M Knudsen; Benedikte Bandak; Ramin Tehranchi
Journal:  Diabetes Care       Date:  2021-06-01       Impact factor: 19.112

2.  Not only for caregivers: intranasal glucagon for severe hypoglycaemia in a simulation study.

Authors:  A Monzani; S Savastio; A Manzo; A Scalogna; E Pozzi; P P Sainaghi; F Della Corte; I Rabbone
Journal:  Acta Diabetol       Date:  2022-08-11       Impact factor: 4.087

3.  Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies.

Authors:  Mark P Christiansen; Martin Cummins; Steven Prestrelski; Nicole C Close; Anh Nguyen; Khaled Junaidi
Journal:  BMJ Open Diabetes Res Care       Date:  2021-10

4.  Cost of Severe Hypoglycemia and Budget Impact with Nasal Glucagon in Patients with Diabetes in Spain.

Authors:  Beatrice Osumili; Esther Artime; Beth Mitchell; Miriam Rubio-de Santos; Silvia Díaz-Cerezo; Marga Giménez; Erik Spaepen; Helen Sharland; William J Valentine
Journal:  Diabetes Ther       Date:  2022-03-16       Impact factor: 2.945

5.  A Comparative Study of Dasiglucagon Ready-to-Use Autoinjector and Glucagon Emergency Kit During Rescue from Simulated Severe Hypoglycemia.

Authors:  Naila Celeste Bailey; Jeannett Dimsits; Mette Hammer; David M Kendall; Timothy S Bailey
Journal:  Diabetes Technol Ther       Date:  2021-12-16       Impact factor: 7.337

6.  Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial.

Authors:  Tadej Battelino; Ramin Tehranchi; Timothy Bailey; Klemen Dovc; Anita Melgaard; Jenine Yager Stone; Stephanie Woerner; Thekla von dem Berge; Linda DiMeglio; Thomas Danne
Journal:  Pediatr Diabetes       Date:  2021-06-09       Impact factor: 4.866

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.